Navigation Links
ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
Date:3/31/2008

ADVENTRX Presents Results at Keystone Symposia HIV Pathogenesis Conference

SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced that it presented preclinical results for ANX-201, the Company's broad-spectrum antiviral product candidate at the Keystone Symposia HIV Pathogenesis Conference in Banff, Alberta on March 30, 2008. The preclinical results demonstrate a unique resistance profile for ANX-201 and suggest suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs to treat HIV. The HIV Pathogenesis Conference is part of the Keystone Symposia Global Health Series, which is supported by the Bill & Melinda Gates Foundation. The poster presentation entitled "The pyrophosphate analogue thiophosphonoformic acid confers a favorable HIV resistance profile," was presented by Shani Waninger, Ph.D., associate director for research and development at ADVENTRX.

ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) that is being developed to provide benefits for treatment-resistant HIV-infected patients. Foscarnet, the main metabolite of ANX-201, is approved by the FDA for use in immunocompromised patients with CMV retinitis and mucocutaneous acyclovir-resistant HSV infections. However, clinical use of foscarnet is limited, in part due to its intravenous administration and low oral bioavailability. In contrast, in vivo tests have demonstrated increased oral bioavailability of ANX-201, relative to foscarnet, potentially enabling oral delivery.

The preclinical data presented at the conference show that virus selected for resistance to ANX-201 develop genetic muta
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
2. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
3. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
4. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
5. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
6. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
8. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
9. Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
10. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
11. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram Devices ... 2016. The North America accounts ... while Europe claims approximately 27% ...
(Date:12/15/2014)... YORK and HERZLIYA PITUACH, Israel ... "Company") (NASDAQ: IMNP ) announced today that its ... the Board succeeding Dr. Daniel Teper who continues ... a member of Immune,s Board of Directors since 2013. ... "I am delighted to represent the interest of shareholders and ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... LAKE, N.J., Jan. 3, 2012  Arena Pharmaceuticals, Inc. (NASDAQ: ... has submitted its response to the Complete Response Letter (CRL) ... review of the lorcaserin New Drug Application (NDA). Lorcaserin is ... weight loss, in patients who are obese (Body Mass Index, ...
... Jan. 3, 2012 IDEXX Laboratories, Inc. (NASDAQ: ... 30 th Annual J.P. Morgan Healthcare Conference. Jonathan W. ... on the Company on Monday, January 9, 2012 at 2:30 ... California. Individuals can access the live audio webcast of the ...
Cached Medicine Technology:Arena Submits Response to FDA Complete Response Letter for Lorcaserin 2Arena Submits Response to FDA Complete Response Letter for Lorcaserin 3Arena Submits Response to FDA Complete Response Letter for Lorcaserin 4Arena Submits Response to FDA Complete Response Letter for Lorcaserin 5Arena Submits Response to FDA Complete Response Letter for Lorcaserin 6
(Date:12/19/2014)... Albuquerque, New Mexico (PRWEB) December 19, 2014 ... pain relief industry is excited to announce a new ... gauss rare earth magnets. These are the strongest neodymium ... therapy necklace. Pain Free Living developed the Superior Magnetics ... magnets. , “Pain Free Living performs magnetic therapy using ...
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga ... 2014 in its Goa retreat . This is the ... winters, from November to March, Siddhi Yoga will organize four ... Goa. The Goa training sessions will conclude in March 2015. ... training, the 10th intake is also a 200 YTT ...
(Date:12/19/2014)... After a 13-year absence from active touring, the ... stage to entertain his many worldwide fans. Trisha Yearwood ... successful tour has been steadily expanding since the very ... Ticketability.com for a large inventory of Garth Brooks ... , Music fans have had a long wait for ...
(Date:12/19/2014)... Consilium Staffing, Your Partner in Locum ... Federal Health Professionals annual meeting in Washington, D.C., ... and federal healthcare providers. , In addition, ... Engagement (NVSBE) conference last week in Atlanta, Georgia. ... solution in addressing our nation’s shortage of physicians,” ...
(Date:12/19/2014)... good shape seems to reduce your risk of high blood ... than 57,000 Americans, including more than 35,000 with high blood ... Those in the poorest shape had a more than 70 ... of the study, compared to a 50 percent chance for ... than 8,000 people diagnosed with high blood pressure during the ...
Breaking Medicine News(10 mins):Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Being Fit Keeps Blood Pressure in Check 2
... For many years, consumers have,been able to take out ... cosmetic surgeries, but they haven,t been able to borrow,money ... could save their,lives., As a result, many drug ... they need., The federal government is aware of ...
... May 14 An estimated 130,000 North,Carolinians suffer ... Easley and his wife Mary are joining the ... of,fibromyalgia during National Women,s Health Week. "It is ... diagnosis and treatment of,fibromyalgia as it often takes ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA.OB) ... from the University of Pennsylvania,s Center for,Research ... the results of,the Company,s sponsored study showing ... and increases fertilizing,capability in mice., The ...
... Marcy Kaptur (D-Ohio) received the annual Joseph F. Boyle ... of Physicians (ACP) last night. The award is given ... an official capacity who has provided outstanding public service ... presenting the award to Rep. Kaptur, David L. Bronson, ...
... The latest information on the biology and treatment of testicular ... presented at the Symposium on Testicular Cancer organized by the ... 15-16 May in Munich, Germany. , "Testicular cancer is the ... and thirty-five and has seen the strongest increase in incidence ...
... /Xinhua-PRNewswire-FirstCall/ -- China Nepstar,Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number ... with the Shenzhen Charity,Federation to organize a program ... earthquake in Sichuan province, China. Specifically, the program ...
Cached Medicine News:Health News:A Better Tomorrow Becomes One of the First Rehabilitation Clinics in the Nation to Offer Financing for Its Drug, Alcohol and Gambling Treatment Programs 2Health News:Triangle Group Raises Awareness of Fibromyalgia 2Health News:Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals 2Health News:Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals 3Health News:Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals 4Health News:Ohio congresswoman cited by American College of Physicians 2Health News:Symposium focuses on curable cancer that affects young men 2Health News:China Nepstar Chain Drugstore Organizing An Earthquake Relief Program 2Health News:China Nepstar Chain Drugstore Organizing An Earthquake Relief Program 3
Porous foundation 470 series....
The Opteon stem meets the challenge of providing a high-quality, cost-effective hip implant for the moderate demand patient....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The link ribbed hip stem for cementless primary hip replacement surgery....
Medicine Products: